Table 1 FDA-approved nanomedicines7,16,52,291

From: Engineering precision nanoparticles for drug delivery

Drug Company Application Date of first approval
Lipid-based
Doxil Janssen Kaposi’s sarcoma, ovarian cancer, multiple myeloma 1995
DaunoXome Galen Kaposi’s sarcoma 1996
AmBisome Gilead Sciences Fungal/protozoal infections 1997
Visudyne Bausch and Lomb Wet age-related macular degeneration, myopia, ocular histoplasmosis 2000
Marqibo Acrotech Biopharma Acute lymphoblastic leukaemia 2012
Onivyde Ipsen Metastatic pancreatic cancer 2015
Vyxeos Jazz Pharmaceuticals Acute myeloid leukaemia 2017
Onpattro Alnylam Pharmaceuticals Transthyretin-mediated amyloidosis 2018
Polymer-based
Oncaspar Servier Pharmaceuticals Acute lymphoblastic leukaemia 1994
Copaxone Teva Multiple sclerosis 1996
PegIntron Merck Hepatitis C infection 2001
Eligard Tolmar Prostate cancer 2002
Neulasta Amgen Neutropenia, chemotherapy induced 2002
Abraxane Celgene Lung cancer, metastatic breast cancer, metastatic pancreatic cancer 2005
Cimiza UCB Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis 2008
Plegridy Biogen Multiple sclerosis 2014
ADYNOVATE Takeda Haemophilia 2015
Inorganic
INFeD Allergan Iron-deficient anaemia 1992
DexFerrum American Regent Iron-deficient anaemia 1996
Ferrlecit Sanofi Iron deficiency in chronic kidney disease 1999
Venofer American Regent Iron deficiency in chronic kidney disease 2000
Feraheme AMAG Iron deficiency in chronic kidney disease 2009
Injectafer American Regent Iron-deficient anaemia 2013